

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for selectively inhibiting Cox-2 relative to Cox-1 comprising the steps of:

administering a pre-determined dose of processed *Morinda citrifolia* juice to a patient two-times-per-day wherein said *Morinda citrifolia* juice is present in an amount of about 2.31 percent by volume; and limiting undesired COX-1 inhibition relative to COX-2 inhibition.
2. (Cancelled)
3. (Original) The method of claim 1, wherein the *Morinda citrifolia* is in liquid form.
4. (Original) The method of claim 1, wherein the *Morinda citrifolia* is included as an ingredient in a food product.
5. (Original) The method of claim 1, wherein the *Morinda citrifolia* is in capsule form.
6. (Original) The method of claim 1, wherein said dose of *Morinda citrifolia* inhibits the production of COX-2 related prostaglandins that cause pain and inflammation and inhibits to a lesser extent, the production of COX-1 related prostaglandins.

7. (Original) The method of claim 1, wherein said dose of *Morinda citrifolia* is administered at a predetermined concentration.
8. (Original) The method of claim 7, wherein said *Morinda citrifolia* is included as an ingredient in another food product.
9. (Currently Amended) A method of treating pain and inflammation comprising the steps of:
  - obtaining a quantity of *Morinda citrifolia* juice and pulp;
  - filtering the wet pulp from the juice;
  - pasteurizing the juice; and
  - providing a therapeutic dose of said *Morinda citrifolia* juice for consumption in ~~an amount between about 2 and 3 ounces,~~ wherein said *Morinda citrifolia* juice is present in an amount of ~~about~~ 2.31 percent by volume to limit undesired COX-1 inhibition relative to COX-2 inhibition.
10. (Original) The method of claim 9, wherein the *Morinda citrifolia* juice is included as an ingredient in a food product.
11. (Cancelled)

12. (Currently Amended) A method of treating pain and inflammation comprising the steps of:

obtaining a quantity of *Morinda citrifolia* juice and pulp;

filtering the wet pulp from the juice, wherein the wet pulp has a fiber content of from 10% to 40%, by weight;

pasteurizing the pulp; and

providing a therapeutic dose of said *Morinda citrifolia* pulp for consumption by a patient, wherein said *Morinda citrifolia* juice is present in an amount of about 2.31 percent by volume for limiting undesired COX-1 inhibition relative to COX-2 inhibition.

13. (Original) The method of claim 12, wherein the *Morinda citrifolia* pulp is included as an ingredient in a food product.

14. (Cancelled)